CGRP Forum has been reporting live from the the 13th European Headache Congress in Athens, Greece, and highlights from the first two days have included a call to action to accelerate access to new migraine treatments, and latest data on anti-CGRP therapies.
 |
Act now to accelerate access to new migraine treatments
Clinicians, patients and pharmaceutical companies must join forces to campaign for healthcare payers and providers to make migraine a priority and accelerate access to new treatments. This was the clear message from organisers of the European Headache Federation Congress 2019 on the opening day of the meeting.
Read more »
|
 |
New data from FOCUS trial show fremanezumab benefits in episodic and chronic migraine
New data from the Phase 3b FOCUS trial have demonstrated the efficacy of quarterly and monthly fremanezumab treatment in patients with episodic and chronic migraine who had inadequate responses to two to four previous preventive therapies.
Read more »
|
 |
Advantageous placebo and nocebo profile of anti-CGRP therapies may promote treatment success
Results of a meta analysis of placebo and nocebo responses in anti-CGRP monoclonal antibody trials suggest a higher than average placebo incidence and average/low nocebo phenomenon compared with standard therapies for episodic and chronic migraine.
Read more »
|
 |
PROMISE-2 results show consistent eptinezumab efficacy in chronic migraine following two infusions
Significant improvements in monthly migraine activity seen with the first infusion of eptinezumab in the PROMISE-2 study of chronic migraine have been sustained with an additional quarterly infusion. Extended data, presented by Dr Roger Cady, from Alder BioPharmaceuticals, show that effects on monthly migraine days and responder rates were maintained through months 4-6 of treatment.
Read more »
|
For all the other recent migraine news featured on the CGRP Forum click here »
| Becoming a member is easy
Members have free open access simply by registering online. | |
